孙广浩;刘薇;邵润霞;

• 1:郑州大学第二附属医院呼吸内科

摘要(Abstract)：

目的探讨多索茶碱联合乌美溴铵维兰特罗吸入粉雾剂治疗慢性阻塞性肺疾病(COPD)临床疗效,以及对COPD患者短期预后的影响。方法选取2019年9月至2020年8月医院收治的COPD患者100例,按随机数表法分为观察组(n=50)和对照组(n=50)。观察组给予多索茶碱联合乌美溴铵维兰特罗吸入粉雾剂治疗,对照组给予噻托溴铵粉吸入剂治疗。观察分析2组的临床疗效和不良反应,肺通气功能和血气分析指标,以及炎症指标水平,并随访再次急性加重情况。结果观察组的总有效率高于对照组(Z=-1.968, P <0.05),不良反应发生率与对照组相当(P> 0.05)。2组患者治疗后肺通气功能指标(FEV1、FEV1/FVC),血气分析指标(PaO_2、PaCO_2)和系统炎性指标(IL-6、IL-10和CRP水平)均有显著改善,且观察组改善程度大于对照组(P <0.05)。观察组治疗方案可延缓再次急性加重事件的发生(P <0.05)。结论多索茶碱联合乌美溴铵维兰特罗吸入粉雾剂可显著改善COPD患者的肺通气功能,减轻机体炎症反应,临床疗效更佳,安全性可靠,且能降低再次急性加重风险。

关键词(KeyWords)： 多索茶碱;噻托溴铵;乌美溴铵维兰特罗;慢性阻塞性肺疾病

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 孙广浩;刘薇;邵润霞;

DOI: 10.19577/j.1007-4406.2022.01.011

参考文献(References)：

• [1]徐瑜,罗百灵.慢性阻塞性肺疾病急性加重期患者血清hs-CRP、CA-125和IL-6水平变化及临床意义[J].临床肺科杂志,2017,22(3):458.
• [2]吴雨珊,金寿德,强丽霞,等.IL-1β、IL-6及TNF-α在慢性阻塞性肺疾病中的作用及研究进展[J].国际呼吸杂志,2021,41(4):298.
• [3]MALTAIS F,KIRSTEN A M,HAMILTON A,et al.Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease:results from two 6-week crossover studies[J].Respir Res,2016,17(1):77.
• [4]CRINER G,DUFFY S.Reducing and managing chronic obstructive pulmonary disease exacerbations with tiotropium+olodaterol[J].Curr Med Res Opin,2021,37(2):275.
• [5]CAZZOLA M,CALZETTA L,ROGLIANI P,et al.Impact of doxofylline in COPD:a pairwise meta-analysis[J].Pulm Pharmacol Ther,2018,51:1.
• [6]ZHANG Y,LI Y,SHI C,et al.Angiotensin-(1-7)-mediated Mas1receptor/NF-κB-p65 signaling is involved in a cigarette smokeinduced chronic obstructive pulmonary disease mouse model[J].Environ Toxicol,2018,33(1):5.
• [7]ZHOU L T,LIU Y,CHEN X,et al.Over-expression of nuclear factor-κB family genes and inflammatory molecules is related to chronic obstructive pulmonary disease[J].Int J Chron Obstruct Pulmon Dis,2018,13:2131.
• [8]TSUKAGOSHI H,SHIMIZU Y,IWAMAE S,et al.Evidence of oxidative stress in asthma and COPD:potential inhibitory effect of theophylline[J].Respir Med,2000,94(6):584.
• [9]孙冰清,赵洪文.多索茶碱联合噻托溴铵治疗慢性阻塞性肺疾病的疗效及安全性评价[J].国际呼吸杂志,2020,40(17):1287.
• [10]汪长征.多索茶碱联合噻托溴铵粉治疗慢性阻塞性肺疾病的效果观察[J].临床合理用药杂志,2016,9(32):48.
• [11]慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组.慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2014年修订版)[J].国际呼吸杂志,2014,34(1):1.
• [12]WATZ H,TROOSTERS T,BEEH K M,et al.ACTIVATE:the effect of aclidinium/formoterol on hyperinflation,exercise capacity,and physical activity in patients with COPD[J].Int JChronic Obstr Pulm Dis,2017,12:2545.
• [13]BOURBEAU J,LAVOIE K L,SEDENO M,et al.Behaviourchange intervention in a multicentre,randomised,placebocontrolled COPD study:methodological considerations and implementation[J].BMJ Open,2016,6(4):e010109.
• [14]TROOSTERS T,BOURBEAU J,MALTAIS F,et al.Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions:PHYSACTO randomised,placebo-controlled study design[J].BMJ Open,2016,6(4):e010106.